03.18.14
A new study published in Evidence-Based Complementary and Alternative Medicine demonstrated that administration of a combination of LJ100 (200 mg) Eurycoma longfiolia and Polygonum minus (100 mg) exerted significant sexual performance enhancements over placebo.
The 12-week randomized, double-blind, placebo-controlled, parallel-group study, evaluated a total of 26 healthy men aged 40-65. Subjects who passed screening were randomized. Baseline endpoint data was collected and product was dispensed. Subjects returned for two more visits at week 6 and week 12, where completed diaries and any remaining study product were returned, labs were drawn, and a series of scales and questionnaires were administered. Diaries were completed after each sexual intercourse attempt. Safety labs were repeated at the conclusion of the
study at week 12. Further, during the study, subjects were instructed not to alter their current diet and exercise habits.
Those men in the LJ100 group reported a significant increase in sexual satisfaction after 12 weeks, from 15.77 at baseline up to 19.85; the placebo group had a very modest increase, from 12. 36 to 14.29. Erection time from baseline through 12 weeks in the LJ 100 group increased by 12%; the placebo group had a moderate increase of almost 5%. Further, total testosterone in the LJ100 group increased by 10.36%, compared to only 4.28% in the placebo group.
The authors concluded that the combination of LJ100 and Polygonum minus "significantly improved sexual performance across several clinically important parameters after 12 weeks when compared to placebo.” In addition, the product was well tolerated, with excellent safety profiles (identical to placebo) at the administered dose of 300 mg daily for 12 weeks. The results of this study suggest that this product may be of interest to generally healthy middle-aged men who desire improved sexual performance and health.
For more information: www.hpingredients.com
The 12-week randomized, double-blind, placebo-controlled, parallel-group study, evaluated a total of 26 healthy men aged 40-65. Subjects who passed screening were randomized. Baseline endpoint data was collected and product was dispensed. Subjects returned for two more visits at week 6 and week 12, where completed diaries and any remaining study product were returned, labs were drawn, and a series of scales and questionnaires were administered. Diaries were completed after each sexual intercourse attempt. Safety labs were repeated at the conclusion of the
study at week 12. Further, during the study, subjects were instructed not to alter their current diet and exercise habits.
Those men in the LJ100 group reported a significant increase in sexual satisfaction after 12 weeks, from 15.77 at baseline up to 19.85; the placebo group had a very modest increase, from 12. 36 to 14.29. Erection time from baseline through 12 weeks in the LJ 100 group increased by 12%; the placebo group had a moderate increase of almost 5%. Further, total testosterone in the LJ100 group increased by 10.36%, compared to only 4.28% in the placebo group.
The authors concluded that the combination of LJ100 and Polygonum minus "significantly improved sexual performance across several clinically important parameters after 12 weeks when compared to placebo.” In addition, the product was well tolerated, with excellent safety profiles (identical to placebo) at the administered dose of 300 mg daily for 12 weeks. The results of this study suggest that this product may be of interest to generally healthy middle-aged men who desire improved sexual performance and health.
For more information: www.hpingredients.com
